Improvements in health-related quality of life with sumatriptan treatment for migraine

Journal of Family Practice

Volumn 42, Issue 1, 1996, Pages 36-42

  Jhingran, Priti ^a   Cady, Roger K ^b   Rubino, John ^a   Miller, David ^a   Grice, Robert B ^a   Gutterman, Donna L ^a  

^a GLAXOSMITHKLINE   (United States)

^b Clinvest   (United States)

Author keywords

headache; health related quality of life; migraine; Sumatriptan

Indexed keywords

SUMATRIPTAN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DRUG EFFICACY; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; ORAL DRUG ADMINISTRATION; QUALITY OF LIFE; SELF REPORT; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; DISABLED PERSONS; EFFICIENCY; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; QUALITY OF LIFE; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 0030050187     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Cypress B. Headache as the reason for office visits. National Ambulatory Medical Care Survey, United States. NCHS Advance Data 1981; 67:1-6.
2. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache 1993; 33:29-35.
3. Osterhaus JR, Gutterman DL, Plachetka JR. Healthcare resource use and lost labour costs of migraine headache in the US. Pharmacocconomics 1992; 2:67-76.
4. Dahlof C. Assessment of health-related quality of life in migraine. Cephalalgia 1993;13:233-7.
5. Osterhaus JT, Townsend RJ, Gandek B, Ware JE. Measuring the functional status and well-being of patients with migraine headache. Headache 1994; 34:337-43.
6. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan N Engl J Med 1991; 325:316-21.
7. Cady RK, Wendt JK, Kirchner JF, Sargent JD, Rothrock JF, Skaggs H Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991; 265:2831-5.
8. The Oral Sumatriptan Dose-Defining Study Group. Sumatriptan - an oral dose-defining study. Eur Neurol 1991; 31:300-5.
9. The Oral Sumatriptan International Multiple-Dose Study Group. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol 1991; 31.306-13.
10. Ware JE. SF-36 health survey: manual and interpretation guide. Boston, Mass: New England Medical Center, 1993.
11. Ware JE, Shcrbournc CD. The MOS-36-itcm short-form health survey (SF-36). Med Care 1992; 30:473-83.
12. Miller DW, Kirchdoerfer LJ, Shepherd MD, et al. A disease-specific instrument to measure quality of life effects attributable to migraine. Poster presentation at the Health Services Research Association 10th Annual Meeting, Washington, DC, June 27-29, 1993.
13. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA 1989; 262:907-13.
14. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA 1989; 262:914-9.
15. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8:1-96
16. Grice RB, Due D, Fox AW, Davis RL. Evaluation of sumatriptan in the treatment of migraine pain recurrence [abstract]. Headache Q 1993; 4:259-60.